Molecule to Medicine Backs UQ Startup Curlew Bio in Biotech Breakthrough
Exciting news in the biotech space! Global biotech group Molecule to Medicine (MTM) is making waves again by backing Curlew Bio , a brand-new startup from The University of Queensland (UQ) . This partnership is part of MTM’s ambitious push to uncover groundbreaking treatments for inflammatory diseases, and it’s already generating a buzz in the industry.
Now, if you haven’t heard of Molecule to Medicine , they specialize in co-founding and scaling biotech companies, and they’re no strangers to success. The group was founded by Kirsty and Tom McCarthy , the same minds behind Spinifex Pharmaceuticals , a UQ startup that was sold to Novartis for a whopping US$200 million back in 2015. Clearly, they know how to spot promising biotech ventures, and they’re hoping Curlew Bio could be the next big thing.
Also Read:- Strong Winds and Rain Impact Neuquén and RÃo Negro
- How Daylight Saving Time Affects Your Health and How to Prepare
Curlew Bio was formed through UniQuest , UQ’s commercialisation arm, and is already leveraging some serious research power. A key player in this initiative is Honorary Professor Katharina Ronacher from the Mater Research Institute-UQ , who, along with her team, has uncovered a new immunological pathway that could be a game-changer in treating inflammatory diseases. She believes that this discovery has the potential to be turned into real-world medical treatments, improving lives on a significant scale.
Backing up this vision, UniQuest CEO Dr. Dean Moss is emphasizing how this collaboration is about turning cutting-edge research into tangible biotech solutions . With the UniQuest Extension Fund investing $1 million into Curlew Bio, the startup is already gaining strong momentum. Meanwhile, MTM CEO Kirsty McCarthy highlighted their commitment to working with top-tier scientists like Professor Ronacher and using MTM’s expertise in company formation and drug development to fast-track this promising biotech innovation.
Curlew Bio isn’t the only UQ startup MTM has supported. Late last year, they launched Lucia Bio , another biotech company focused on tackling neuroinflammation —which could provide breakthroughs for conditions like Alzheimer’s, Parkinson’s, and motor neuron disease . With this latest addition, MTM’s portfolio now includes six biotech startups spread across Australia and the UK .
This is another strong example of how Australian biotech is gaining global recognition . UQ’s research continues to attract major investors, and with MTM’s backing, Curlew Bio has a real shot at delivering groundbreaking treatments. It’s an exciting time for medical innovation, and we’ll be keeping an eye on how this unfolds!
Read More:
0 Comments